We look forward to more progress in the Actos litigation as it moves towards its first trials next year.
New York, New York (PRWEB) October 20, 2013
Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) that allege long-term use of the Type 2 diabetes drug caused patients to develop bladder cancer continue to move forward in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. According to court documents, the proceeding’s next Case Management Conference will be held on Thursday, October 24, 2013, at 10:30 a.m. (In re: Actos Product Liability Litigation, MDL No. 2299)
“We look forward to more progress in the Actos litigation as it moves towards its first trials next year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of the drug.
According to court documents Actos litigation involving bladder cancer allegations got underway shortly after the U.S. Food & Drug Administration (FDA) warned in June 2011 that use of the drug for 12 months or more had been associated with an increased risk of the disease. At that time, the FDA ordered Takeda Pharmaceuticals to add new warnings to the Actos label about its potential to cause bladder cancer.
Court filings indicate that more than 2,500 Actos lawsuits are now pending in the Western District of Louisiana, where the first case will go to trial in January. Plaintiffs in Actos lawsuits allege that Takeda Pharmaceuticals and other defendants concealed knowledge that the medication could increase a person’s chances of developing bladder cancer, and failed to provide adequate warnings about that risk to the public and medical community.
On the state level, two Actos claims involving bladder cancer allegations have already gone to trial. Last month, a Maryland State Court jury awarded $1.7 million to the family of a man who died of bladder cancer following long-term use of Actos. However, according to court records, the judge presiding over the trial tossed out the verdict because the jury also found that the decedent’s decades-long smoking habit contributed to the development of the disease. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)
This past April, a Los Angeles Superior Court jury awarded $6.5 million to a plaintiff who developed bladder cancer following four years of Actos use. However, the plaintiff is currently appealing a decision by the judge overseeing the case to grant Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Long-term users of Actos who have been diagnosed with bladder cancer may be eligible to file an Actos lawsuit against Takeda Pharmaceuticals. Learn More about Actos and bladder cancer by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP